Neutrophils in cancer: Two sides of the same coin

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Uribe Querol, Eileen ^a   Rosales, Carlos ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CATHEPSIN G; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; LEUKOCYTE ELASTASE; NEUTROPHIL COLLAGENASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOCARCINOMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; COLON CANCER; CYTOKINE PRODUCTION; EXTRACELLULAR TRAP; GLIOMA; HEAD AND NECK CANCER; HUMAN; LEUKOCYTE ACTIVATION; LIVER CELL CARCINOMA; MELANOMA; METASTASIS; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL LYMPHOCYTE RATIO; NEUTROPHILIA; NON SMALL CELL LUNG CANCER; PHENOTYPE; REVIEW; SOLID TUMOR; SUPPRESSOR CELL; TUMOR ASSOCIATED NEUTROPHIL; TUMOR MICROENVIRONMENT; ANIMAL; CARCINOGENESIS; CELL MOTION; CELLULAR IMMUNITY; IMMUNOLOGY; NEOPLASM;

ANIMALS; CARCINOGENESIS; CELL MOVEMENT; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; NEUTROPHILS; TUMOR MICROENVIRONMENT;

EID: 84954570886     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/983698     Document Type: Review

References (222)

1. N. Borregaard, "Neutrophils, frommarrow tomicrobes, " Immunity, vol. 33, no. 5, pp. 657-670, 2010.
2. E. Kolaczkowska and P. Kubes, "Neutrophil recruitment and function in health and inflammation, " Nature Reviews Immunology, vol. 13, no. 3, pp. 159-175, 2013.
3. C. T. N. Pham, "Neutrophil serine proteases: specific regulators of inflammation, " Nature Reviews Immunology, vol. 6, no. 7, pp. 541-550, 2006.
4. P. Scapini, J. A. Lapinet-Vera, S. Gasperini, F. Calzetti, F. Bazzoni, and M. A. Cassatella, "The neutrophil as a cellular source of chemokines, " Immunological Reviews, vol. 177, pp. 195-203, 2000.
5. C. Tecchio, P. Scapini, G. Pizzolo, and M. A. Cassatella, "On the cytokines produced by human neutrophils in tumors, " Seminars in Cancer Biology, vol. 23, no. 3, pp. 159-170, 2013.
6. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation, " Nature, vol. 454, no. 7203, pp. 436-444, 2008.
7. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
8. A. D. Gregory and A. M. Houghton, "Tumor-associated neutrophils: new targets for cancer therapy, " Cancer Research, vol. 71, no. 7, pp. 2411-2416, 2011.
9. A. Mantovani, M. A. Cassatella, C. Costantini, and S. Jaillon, "Neutrophils in the activation and regulation of innate and adaptive immunity, " Nature Reviews Immunology, vol. 11, no. 8, pp. 519-531, 2011.
10. M. Wislez, N. Rabbe, J. Marchal et al. , "Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death, " Cancer Research, vol. 63, no. 6, pp. 1405-1412, 2003.
11. H. Schmidt, L. Bastholt, P. Geertsen et al. , "Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model, " British Journal of Cancer, vol. 93, no. 3, pp. 273-278, 2005.
12. H. K. Jensen, F. Donskov, N. Marcussen, M. Nordsmark, F. Lundbeck, and H. von der Maase, "Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma, " Journal of Clinical Oncology, vol. 27, no. 28, pp. 4709-4717, 2009.
13. S. Trellakis, K. Bruderek, C. A. Dumitru et al. , "Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease, " International Journal of Cancer, vol. 129, no. 9, pp. 2183-2193, 2011.
14. Z. G. Fridlender and S. M. Albelda, "Tumor-associated neutrophils: friend or foe?" Carcinogenesis, vol. 33, no. 5, pp. 949-955, 2012.
15. Z. G. Fridlender, J. Sun, S. Kim et al. , "Polarization of tumorassociated neutrophil phenotype by TGF-β: N1 versus N2 TAN, " Cancer Cell, vol. 16, no. 3, pp. 183-194, 2009.
16. M. R. Galdiero, C. Garlanda, S. Jaillon, G. Marone, and A. Mantovani, "Tumor associated macrophages and neutrophils in tumor progression, " Journal of Cellular Physiology, vol. 228, no. 7, pp. 1404-1412, 2013.
17. R. V. Sionov, Z. G. Fridlender, and Z. Granot, "Themultifaceted roles neutrophils play in the tumor microenvironment, " Cancer Microenvironment, pp. 1-34, 2014.
18. A. Swierczak, K. A. Mouchemore, J. A. Hamilton, and R. L. Anderson, "Neutrophils: important contributors to tumor progression and metastasis, " Cancer and Metastasis Reviews, 2015.
19. C. T. McGary, M. E. Miele, and D. R. Welch, "Highly metastatic 13762NF rat mammary adenocarcinoma cell clones stimulate bone marrow by secretion of granulocyte-macrophage colonystimulating factor/interleukin-3 activity, " The American Journal of Pathology, vol. 147, no. 6, pp. 1668-1681, 1995.
20. M. G. Lechner, D. J. Liebertz, and A. L. Epstein, "Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells, " The Journal of Immunology, vol. 185, no. 4, pp. 2273-2284, 2010.
21. J. Atzpodien and M. Reitz, "Peripheral blood neutrophils as independent immunologic predictor of response and longterm survival upon immunotherapy in metastatic renal-cell carcinoma, " Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 1, pp. 129-134, 2008.
22. A. Bellocq, M. Antoine, A. Flahault et al. , "Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome, " The American Journal of Pathology, vol. 152, no. 1, pp. 83-92, 1998.
23. M. D. Reid, O. Basturk, D. Thirabanjasak et al. , "Tumorinfiltrating neutrophils in pancreatic neoplasia, "Modern Pathology, vol. 24, no. 12, pp. 1612-1619, 2011.
24. K. J. Halazun, M. A. Hardy, A. A. Rana et al. , "Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma, " Annals of Surgery, vol. 250, no. 1, pp. 141-151, 2009.
25. S. R. Walsh, E. J. Cook, F. Goulder, T. A. Justin, and N. J. Keeling, "Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer, " Journal of Surgical Oncology, vol. 91, no. 3, pp. 181-184, 2005.
26. B. Peng, Y.-H. Wang, Y.-M. Liu, and L.-X. Ma, "Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and metaanalysis, " International Journal of Clinical and Experimental Medicine, vol. 8, no. 3, pp. 3098-3106, 2015.
27. J.-R. He, G.-P. Shen, Z.-F. Ren et al. , "Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma, " Head and Neck, vol. 34, no. 12, pp. 1769-1776, 2012.
28. G. Malietzis, M. Giacometti, R. H. Kennedy, T. Athanasiou, O. Aziz, and J. T. Jenkins, "The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis, " Annals of Surgical Oncology, vol. 21, no. 12, pp. 3938-3946, 2014.
29. S. Krenn-Pilko, U. Langsenlehner, E.-M. Thurner et al. , "The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients, " British Journal of Cancer, vol. 110, no. 10, pp. 2524-2530, 2014.
30. M. Pistelli, M. De Lisa, Z. Ballatore et al. , "Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients, " BMC Cancer, vol. 15, article 195, 2015.
31. G. J. K. Guthrie, K. A. Charles, C. S. D. Roxburgh, P. G. Horgan, D. C. McMillan, and S. J. Clarke, "The systemic inflammationbased neutrophil-lymphocyte ratio: experience in patients with cancer, " Critical Reviews Oncology and Hematology, vol. 88, no. 1, pp. 218-230, 2013.
32. A. J. Templeton, M. G. McNamara, B. Seruga et al. , "Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis, " Journal of the National Cancer Institute, vol. 106, no. 6, Article ID dju124, 2014.
33. A. Paramanathan, A. Saxena, and D. L. Morris, "A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours, " SurgicalOncology, vol. 23, no. 1, pp. 31-39, 2014.
34. R. A. Caruso, R. Bellocco, M. Pagano, G. Bertoli, L. Rigoli, and C. Inferrera, "Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in Northern Italy, " Modern Pathology, vol. 15, no. 8, pp. 831-837, 2002.
35. A. H. Pickaver, N. A. Ratcliffe, A. E. Williams, and H. Smith, "Cytotoxic effects of peritoneal neutrophils on a syngeneic rat tumour, " Nature: New biology, vol. 235, no. 58, pp. 186-187, 1972.
36. T. L. Gerrard, D. J. Cohen, and A. M. Kaplan, "Human neutrophil-mediated cytotoxicity to tumor cells, " Journal of the National Cancer Institute, vol. 66, no. 3, pp. 483-488, 1981.
37. M. Katano and M. Torisu, "Neutrophil-mediated tumor cell destruction in cancer ascites, " Cancer, vol. 50, no. 1, pp. 62-68, 1982.
38. Y. Ishihara, H. Lijima, and K. Matsunaga, "Contribution of cytokines on the suppression of lung metastasis, " Biotherapy, vol. 11, no. 4, pp. 267-275, 1998.
39. Y. Ishihara, T. Fujii, H. Iijima, K. Saito, and K. Matsunaga, "The role of neutrophils as cytotoxic cells in lung metastasis: suppression of tumor cell metastasis by a biological response modifier (PSK), " In Vivo, vol. 12, no. 2, pp. 175-182, 1998.
40. J. Yan, G. Kloecker, C. Fleming et al. , "Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells, " OncoImmunology, vol. 3, no. 7, Article ID e950163, 2014.
41. S. Brandau, C. A. Dumitru, and S. Lang, "Protumor and antitumor functions of neutrophil granulocytes, " Seminars in Immunopathology, vol. 35, no. 2, pp. 163-176, 2013.
42. B. Almand, J. I. Clark, E. Nikitina et al. , "Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer, "The Journal of Immunology, vol. 166, no. 1, pp. 678-689, 2001.
43. J. Choi, B. Suh, Y. Ahn et al. , "CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloidderived suppressor cells that have suppressive function, " Tumor Biology, vol. 33, no. 1, pp. 121-129, 2012.
44. E. Peranzoni, S. Zilio, I. Marigo et al. , "Myeloid-derived suppressor cell heterogeneity and subset definition, " Current Opinion in Immunology, vol. 22, no. 2, pp. 238-244, 2010.
45. P. L. Raber, P. Thevenot, R. Sierra et al. , "Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways, " International Journal of Cancer, vol. 134, no. 12, pp. 2853-2864, 2014.
46. J.-I. Youn, S. Nagaraj, M. Collazo, and D. I. Gabrilovich, "Subsets of myeloid-derived suppressor cells in tumor-bearing mice, " Journal of Immunology, vol. 181, no. 8, pp. 5791-5802, 2008.
47. D. I. Gabrilovich and S. Nagaraj, "Myeloid-derived suppressor cells as regulators of the immune system, " Nature Reviews Immunology, vol. 9, no. 3, pp. 162-174, 2009.
48. S. Nagaraj, A. G. Schrum, H.-I. Cho, E. Celis, and D. I. Gabrilovich, "Mechanism of T cell tolerance induced by myeloid-derived suppressor cells, " The Journal of Immunology, vol. 184, no. 6, pp. 3106-3116, 2010.
49. J. Favaloro, T. Liyadipitiya, R. Brown et al. , "Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma, " Leukemia and Lymphoma, vol. 55, no. 12, pp. 2893-2900, 2014.
50. B. Raychaudhuri, P. Rayman, P. Huang et al. , "Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes, " Journal of Neuro-Oncology, vol. 122, pp. 293-301, 2015.
51. A. Gallamini, F. DiRaimondo, G. LaNasa, A. Romano, A. Borra, and M. Greco, "Standard therapies versus novel therapies in Hodgkin lymphoma, " Immunology Letters, vol. 155, no. 1-2, pp. 56-59, 2013.
52. S. Trellakis, K. Bruderek, J. Hutte et al. , "Granulocytic myeloidderived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colonystimulating factors in head and neck cancer, " Innate Immunity, vol. 19, no. 3, pp. 328-336, 2013.
53. J. Schmielau and O. J. Finn, "Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients, " Cancer Research, vol. 61, no. 12, pp. 4756-4760, 2001.
54. M. Klemke, G. H. Wabnitz, F. Funke, B. Funk, H. Kirchgessner, and Y. Samstag, "Oxidation of cofilin mediates T cell hyporesponsiveness under oxidative stress conditions, " Immunity, vol. 29, no. 3, pp. 404-413, 2008.
55. G. H. Wabnitz, C. Goursot, B. Jahraus et al. , "Mitochondrial translocation of oxidized cofilin induces caspase-independent necrotic-like programmed cell death of T cells, " Cell Death and Disease, vol. 1, article e58, 2010.
56. K.-J. Malmberg, V. Arulampalam, F. Ichihara et al. , "Inhibition of activated/memory (CD45RO+) T cells by oxidative stress associated with block ofNF-κB activation, " Journal of Immunology, vol. 167, no. 5, pp. 2595-2601, 2001.
57. S. Nagaraj, K. Gupta, V. Pisarev et al. , "Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer, " Nature Medicine, vol. 13, no. 7, pp. 828-835, 2007.
58. R. Rotondo, M. Bertolotto, G. Barisione et al. , "Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit t lymphocyte proliferation, " Journal of Leukocyte Biology, vol. 89, no. 5, pp. 721-727, 2011.
59. R. Rotondo, G. Barisione, L. Mastracci et al. , "IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer, " International Journal of Cancer, vol. 125, no. 4, pp. 887-893, 2009.
60. T. R. Sippel, J. White, K. Nag et al. , "Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I, " Clinical Cancer Research, vol. 17, no. 22, pp. 6992-7002, 2011.
61. S. Brandau, K. Moses, and S. Lang, "The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?" Seminars in Cancer Biology, vol. 23, no. 3, pp. 171-182, 2013.
62. S. Brandau, S. Trellakis, K. Bruderek et al. , "Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties, " Journal of Leukocyte Biology, vol. 89, no. 2, pp. 311-317, 2011.
63. Z. G. Fridlender, J. Sun, I. Mishalian et al. , "Transcriptomic analysis comparing tumor-associated neutrophils with granulocyticmyeloid-derived suppressor cells and normal neutrophils, " PLoS ONE, vol. 7, no. 2, Article ID e31524, 2012.
64. I. Mishalian, R. Bayuh, L. Levy, L. Zolotarov, J. Michaeli, and Z. G. Fridlender, "Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression, " Cancer Immunology, Immunotherapy, vol. 62, no. 11, pp. 1745-1756, 2013.
65. E. B. Eruslanov, P. S. Bhojnagarwala, J. G. Quatromoni et al. , "Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer, " Journal of Clinical Investigation, vol. 124, no. 12, pp. 5466-5480, 2014.
66. P. Wu, D. Wu, C. Ni et al. , "γ δT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer, " Immunity, vol. 40, no. 5, pp. 785-800, 2014.
67. J. Y. Sagiv, J. Michaeli, S. Assi et al. , "Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer, " Cell Reports, vol. 10, no. 4, pp. 562-573, 2015.
68. E. Garcia-Garcia, E. Uribe-Querol, and C. Rosales, "A simple and efficient method to detect nuclear factor activation in human neutrophils by flow cytometry, " Journal of Visualized Experiments, no. 74, Article IDe50410, 2013.
69. Z. Granot, E. Henke, E. A. Comen, T. A. King, L. Norton, and R. Benezra, "Tumor entrained neutrophils inhibit seeding in the premetastatic lung, " Cancer Cell, vol. 20, no. 3, pp. 300-314, 2011.
70. J. D. Waight, Q. Hu, A. Miller, S. Liu, and S. I. Abrams, "Tumorderived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism, " PLoS ONE, vol. 6, no. 11, Article ID e27690, 2011.
71. A. Sparmann and D. Bar-Sagi, "Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis, " Cancer Cell, vol. 6, no. 5, pp. 447-458, 2004.
72. H. Ji, A. M. Houghton, T. J. Mariani et al. , "K-ras activation generates an inflammatory response in lung tumors, " Oncogene, vol. 25, no. 14, pp. 2105-2112, 2006.
73. L. A. Pekarek, B. A. Starr, A. Y. Toledano, and H. Schreiber, "Inhibition of tumor growth by elimination of granulocytes, " The Journal of Experimental Medicine, vol. 181, no. 1, pp. 435-440, 1995.
74. H. Tazawa, F. Okada, T. Kobayashi et al. , "Infiltration of neutrophils is required for acquisition of metastatic phenotype of benignmurine fibrosarcomacells: implication of inflammationassociated carcinogenesis and tumor progression, " The American Journal of Pathology, vol. 163, no. 6, pp. 2221-2232, 2003.
75. M. P. Keane, J. A. Belperio, Y. Y. Xue, M. D. Burdick, and R. M. Strieter, "Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer, " Journal of Immunology, vol. 172, no. 5, pp. 2853-2860, 2004.
76. D. J. J. Waugh and C. Wilson, "The interleukin-8 pathway in cancer, " Clinical Cancer Research, vol. 14, no. 21, pp. 6735-6741, 2008.
77. G. Lazennec and A. Richmond, "Chemokines and chemokine receptors: new insights into cancer-related inflammation, " Trends in Molecular Medicine, vol. 16, no. 3, pp. 133-144, 2010.
78. S. Ueha, F. H. W. Shand, and K. Matsushima, "Myeloid cell population dynamics in healthy and tumor-bearing mice, " International Immunopharmacology, vol. 11, no. 7, pp. 783-788, 2011.
79. Y. Kobayashi, "The role of chemokines in neutrophil biology, " Frontiers in Bioscience, vol. 13, no. 7, pp. 2400-2407, 2008.
80. H. Okabe, T. Beppu, M. Ueda et al. , "Identification of CXCL5/ ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts, " International Journal of Cancer, vol. 131, no. 10, pp. 2234-2241, 2012.
81. H. Verbeke, S. Struyf, N. Berghmans et al. , "Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth andmetastasis, " Cancer Letters, vol. 302, no. 1, pp. 54-62, 2011.
82. J. Bernhagen, R. Krohn, H. Lue et al. , "MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment, " Nature Medicine, vol. 13, no. 5, pp. 587-596, 2007.
83. C. A. Dumitru, H. Gholaman, S. Trellakis et al. , "Tumorderived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation, " International Journal of Cancer, vol. 129, no. 4, pp. 859-869, 2011.
84. A. Aruga, E. Aruga, M. J. Cameron, and A. E. Chang, "Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression, " Journal of Leukocyte Biology, vol. 61, no. 4, pp. 507-516, 1997.
85. H. Richards, A. Williams, E. Jones et al. , "Novel role of regulatory T cells in limiting early neutrophil responses in skin, " Immunology, vol. 131, no. 4, pp. 583-592, 2010.
86. M. E. Himmel, S. Q. Crome, S. Ivison, C. Piccirillo, T. S. Steiner, and M. K. Levings, "Human CD4+FOXP3+ regulatory T cells produce CXCL8 and recruit neutrophils, " European Journal of Immunology, vol. 41, no. 2, pp. 306-312, 2011.
87. I. Mishalian, R. Bayuh, E. Eruslanov et al. , "Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17-a new mechanism of impaired antitumor immunity, " International Journal of Cancer, vol. 135, no. 5, pp. 1178-1186, 2014.
88. C. A. Dumitru, K. Moses, S. Trellakis, S. Lang, and S. Brandau, "Neutrophils and granulocyticmyeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology, " Cancer Immunology, Immunotherapy, vol. 61, no. 8, pp. 1155-1167, 2012.
89. B. Korkmaz, T. Moreau, and F. Gauthier, "Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions, " Biochimie, vol. 90, no. 2, pp. 227-242, 2008.
90. T. Sato, S. Takahashi, T. Mizumoto et al. , "Neutrophil elastase and cancer, " Surgical Oncology, vol. 15, no. 4, pp. 217-222, 2006.
91. A. M. Houghton, D. M. Rzymkiewicz, H. Ji et al. , "Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth, " Nature Medicine, vol. 16, no. 2, pp. 219-223, 2010.
92. A. D. Gregory, P. Hales, D. H. Perlmutter, and A. M. Houghton, "Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsinGby cancer cells, " Journal of Biological Chemistry, vol. 287, no. 42, pp. 35341-35350, 2012.
93. D. I. Gabrilovich, V. Bronte, S.-H. Chen et al. , "The terminology issue for myeloid-derived suppressor cells, " Cancer Research, vol. 67, no. 1, p. 425, 2007.
94. Y. Wada, K. Yoshida, Y. Tsutani et al. , "Neutrophil elastase induces cell proliferation and migration by the release of TGF-α, PDGF and VEGF in esophageal cell lines, " Oncology Reports, vol. 17, no. 1, pp. 161-167, 2007.
95. Y. Wada, K. Yoshida, J. Hihara et al. , "Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-α, " Cancer Science, vol. 97, no. 10, pp. 1037-1043, 2006.
96. M. Nawa, S. Osada, K. Morimitsu et al. , "Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy, " Anticancer Research, vol. 32, no. 1, pp. 13-19, 2012.
97. M. M. Gaida, T. G. Steffen, F. Gunther et al. , "Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastasemediated degradation of E-cadherin in pancreatic tumors, " European Journal of Immunology, vol. 42, no. 12, pp. 3369-3380, 2012.
98. A. W. Segal, "How neutrophils kill microbes, " Annual Review of Immunology, vol. 23, pp. 197-223, 2005.
99. R. Morimoto-Kamata, S.-I. Mizoguchi, T. Ichisugi, and S. Yui, "Cathepsin G induces cell aggregation of human breast cancer MCF-7 cells via a 2-step mechanism: Catalytic site-independent binding to the cell surface and enzymatic activity-dependent induction of the cell aggregation, " Mediators of Inflammation, vol. 2012, Article ID456462, 13 pages, 2012.
100. T. J. Wilson, K. C. Nannuru, M. Futakuchi, and R. K. Singh, "Cathepsin G-mediated enhanced TGF-β signaling promotes angiogenesis via upregulation of VEGF and MCP-1, " Cancer Letters, vol. 288, no. 2, pp. 162-169, 2010.
101. S. Yui, Y. Osawa, T. Ichisugi, and R. Morimoto-Kamata, "Neutrophil cathepsin G, but not elastase, induces aggregation of MCF-7 mammary carcinoma cells by a protease activitydependent cell-oriented mechanism, " Mediators of Inflammation, vol. 2014, Article ID 971409, 12 pages, 2014.
102. T. J. Wilson, K. C. Nannuru, and R. K. Singh, "Cathepsin Gmediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-β signaling and bone destruction, " Molecular Cancer Research, vol. 7, no. 8, pp. 1224-1233, 2009.
103. T. J. Wilson, K. C. Nannuru, M. Futakuchi, A. Sadanandam, and R. K. Singh, "Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-κB ligand, " Cancer Research, vol. 68, no. 14, pp. 5803-5811, 2008.
104. L. M. Coussens, C. L. Tinkle, D. Hanahan, and Z. Werb, "MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis, " Cell, vol. 103, no. 3, pp. 481-490, 2000.
105. H. B. Acuff, K. J. Carter, B. Fingleton, D. L. Gorden, and L. M. Matrisian, "Matrixmetalloproteinase-9 from bone marrowderived cells contributes to survival but not growth of tumor cells in the lung microenvironment, " Cancer Research, vol. 66, no. 1, pp. 259-266, 2006.
106. Q. Ebrahem, S. S. Chaurasia, A. Vasanji et al. , "Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo, " American Journal of Pathology, vol. 176, no. 1, pp. 496-503, 2010.
107. L. J. A. C. Hawinkels, K. Zuidwijk, H. W. Verspaget et al. , "VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis, " European Journal of Cancer, vol. 44, no. 13, pp. 1904-1913, 2008.
108. E. V. Coillie, I. V. Aelst, A. Wuyts et al. , "Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle, "American Journal of Pathology, vol. 159, no. 4, pp. 1405-1414, 2001.
109. G. Bergers, R. Brekken, G. McMahon et al. , "Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, " Nature Cell Biology, vol. 2, no. 10, pp. 737-744, 2000.
110. V. Masson, L. R. de la Ballina, C. Munaut et al. , "Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes, " The FASEB Journal, vol. 19, no. 2, pp. 234-236, 2005.
111. S. Jodele, C. F. Chantrain, L. Blavier et al. , "The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinaae-9 dependent, " Cancer Research, vol. 65, no. 8, pp. 3200-3208, 2005.
112. C. F. Chantrain, P. Henriet, S. Jodele et al. , "Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases, " European Journal of Cancer, vol. 42, no. 3, pp. 310-318, 2006.
113. H. Nozawa, C. Chiu, and D. Hanahan, "Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12493-12498, 2006.
114. J. Jablonska, S. Leschner, K. Westphal, S. Lienenklaus, and S. Weiss, "Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model, " The Journal of Clinical Investigation, vol. 120, no. 4, pp. 1151-1164, 2010.
115. E. M. Bekes, B. Schweighofer, T. A. Kupriyanova et al. , "Tumorrecruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation, " American Journal of Pathology, vol. 179, no. 3, pp. 1455-1470, 2011.
116. C. A. Dumitru, M. K. Fechner, T. K. Hoffmann, S. Lang, and S. Brandau, "A novel p38-MAPK signaling axis modulates neutrophil biology in head and neck cancer, " Journal of Leukocyte Biology, vol. 91, no. 4, pp. 591-598, 2012.
117. D.-M. Kuang, Q. Zhao, C. Peng et al. , "Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1, " The Journal of Experimental Medicine, vol. 206, no. 6, pp. 1327-1337, 2009.
118. D.-M. Kuang, Q. Zhao, Y. Wu et al. , "Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma, " Journal of Hepatology, vol. 54, no. 5, pp. 948-955, 2011.
119. E. I. Deryugina, E. Zajac, A. Juncker-Jensen, T. A. Kupriyanova, L. Welter, and J. P. Quigley, "Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment, " Neoplasia, vol. 16, no. 10, pp. 771-788, 2014.
120. E. I. Deryugina and J. P. Quigley, "Tumor angiogenesis: MMPmediated induction of intravasation-and metastasis-sustaining neovasculature, " Matrix Biology, vol. 44-46, pp. 94-112, 2015.
121. Y. Ogata, Y. Itoh, and H. Nagase, "Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases, " Journal of Biological Chemistry, vol. 270, no. 31, pp. 18506-18511, 1995.
122. V. C. Ardi, T. A. Kupriyanova, E. I. Deryugina, and J. P. Quigley, "Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 51, pp. 20262-20267, 2007.
123. V. C. Ardi,P.E.VandenSteen,G.Opdenakker, B. Schweighofer, E. I. Deryugina, and J. P. Quigley, "Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway," The Journal of Biological Chemistry, vol. 284, no. 38, pp. 25854-25866, 2009.
124. J. E. De Larco, B. R. K. Wuertz, and L. T. Furcht, "The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8, " Clinical Cancer Research, vol. 10, no. 15, pp. 4895-4900, 2004.
125. F. Shabani, J. McNeil, and L. Tippett, "The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCl) is suppressed by anti-rheumatic drugs, " Free Radical Research, vol. 28, no. 2, pp. 115-123, 1998.
126. A. M. Knaapen, N. Gungor, R. P. F. Schins, P. J. A. Borm, and F. J. Van Schooten, "Neutrophils and respiratory tract DNA damage and mutagenesis: a review, " Mutagenesis, vol. 21, no. 4, pp. 225-236, 2006.
127. N. Gungor, A. M. Knaapen, A. Munnia et al. , "Genotoxic effects of neutrophils and hypochlorous acid, " Mutagenesis, vol. 25, no. 2, pp. 149-154, 2010.
128. A. Cross, S. W. Edwards, R. C. Bucknall, and R. J. Moots, "Secretion of oncostatin M by neutrophils in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 50, no. 5, pp. 1430-1436, 2004.
129. I. Goren, H. Kampfer, E. Muller, D. Schiefelbein, J. Pfeilschifter, and S. Frank, "Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: implications for normal and diabetes-impairedwounds, " Journal of Investigative Dermatology, vol. 126, no. 3, pp. 628-637, 2006.
130. A. Grenier, D. Combaux, J. Chastre et al. , "Oncostatin M production by blood and alveolar neutrophils during acute lung injury, " Laboratory Investigation, vol. 81, no. 2, pp. 133-141, 2001.
131. A. Grenier, S. Chollet-Martin, B. Crestani et al. , "Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils, " Blood, vol. 99, no. 8, pp. 2997-3004, 2002.
132. A. Matsushima, H. Ogura, T. Koh et al. , "Hepatocyte growth factor in polymorphonuclear leukocytes is increased in patients with systemic inflammatory response syndrome, " Journal of Trauma, vol. 56, no. 2, pp. 259-264, 2004.
133. M. M. Queen, R. E. Ryan, R. G. Holzer, C. R. Keller-Peck, and C. L. Jorcyk, "Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression, " Cancer Research, vol. 65, no. 19, pp. 8896-8904, 2005.
134. Y. Imai, Y. Kubota, S. Yamamoto et al. , "Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study, " Journal of Gastroenterology and Hepatology, vol. 20, no. 2, pp. 287-293, 2005.
135. E. Loukinova, G. Dong, I. Enamorado-Ayalya et al. , "Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism, " Oncogene, vol. 19, no. 31, pp. 3477-3486, 2000.
136. H. Schaider, M. Oka, T. Bogenrieder et al. , "Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8, " International Journal of Cancer, vol. 103, no. 3, pp. 335-343, 2003.
137. D. R. Welch, D. J. Schissel, R. P. Howrey, and P. A. Aeed, "Tumorelicited polymorphonuclear cells, in contrast to normal circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 15, pp. 5859-5863, 1989.
138. C. Strell, K. Lang, B. Niggemann, K. S. Zaenker, and F. Entschladen, "Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1, " Experimental Cell Research, vol. 316, no. 1, pp. 138-148, 2010.
139. Y. Wu, Q. Zhao, C. Peng, L. Sun, X.-F. Li, and D.-M. Kuang, "Neutrophils promotemotility of cancer cells via a hyaluronanmediated TLR4/PI3K activation loop, " The Journal of Pathology, vol. 225, no. 3, pp. 438-447, 2011.
140. Q. D. I. Wu, J. H. Wang, C. Condron, D. Bouchier-Hayes, and H. Paul Redmond, "Human neutrophils facilitate tumor cell transendothelial migration, " The American Journal of Physiology-Cell Physiology, vol. 280, no. 4, pp. C814-C822, 2001.
141. C. Dong, M. J. Slattery, S. Liang, and H.-H. Peng, "Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8, " MCB Molecular and Cellular Biomechanics, vol. 2, no. 3, pp. 145-159, 2005.
142. M. J. Slattery and C. Dong, "Neutrophils influence melanoma adhesion and migration under flow conditions, " International Journal of Cancer, vol. 106, no. 5, pp. 713-722, 2003.
143. Z. Sun and P. Yang, "Role of imbalance between neutrophil elastase and α1-antitrypsin in cancer development and progression, " The Lancet Oncology, vol. 5, no. 3, pp. 182-190, 2004.
144. K. Doi, T. Horiuchi, M. Uchinami et al. , "Neutrophil elastase inhibitor reduces hepatic metastases induced by ischaemiareperfusion in rats, " European Journal of Surgery, vol. 168, no. 8-9, pp. 507-510, 2002.
145. N. Aceto, A. Bardia, D. T. Miyamoto et al. , "Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis, " Cell, vol. 158, no. 5, pp. 1110-1122, 2014.
146. L. A. Liotta, J. Kleinerman, and G. M. Saidel, "The significance of hematogenous tumor cell clumps in the metastatic process, " Cancer Research, vol. 36, no. 3, pp. 889-894, 1976.
147. J. D. Crissman, J. Hatfield, M. Schaldenbrand, B. F. Sloane, and K. V. Honn, "Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study, " Laboratory Investigation, vol. 53, no. 4, pp. 470-478, 1985.
148. S. J. Huh, S. Liang, A. Sharma, C. Dong, and G. P. Robertson, "Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development, " Cancer Research, vol. 70, no. 14, pp. 6071-6082, 2010.
149. J. D. Spicer, B. McDonald, J. J. Cools-Lartigue et al. , "Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells, " Cancer Research, vol. 72, no. 16, pp. 3919-3927, 2012.
150. B. Psaila and D. Lyden, "The metastatic niche: adapting the foreign soil, " Nature Reviews Cancer, vol. 9, no. 4, pp. 285-293, 2009.
151. R. N. Kaplan, S. Rafii, and D. Lyden, "Preparing the soil: the premetastatic niche, " Cancer Research, vol. 66, no. 23, pp. 11089-11093, 2006.
152. R. N. Kaplan, R. D. Riba, S. Zacharoulis et al. , "VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, " Nature, vol. 438, no. 7069, pp. 820-827, 2005.
153. M. Kowanetz, X. Wu, J. Lee et al. , "Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 50, pp. 21248-21255, 2010.
154. H. H. Yan, M. Pickup, Y. Pang et al. , "Gr-1+CD11b+myeloid cells tip the balance ofimmune protection to tumor promotion in the premetastatic lung, " Cancer Research, vol. 70, no. 15, pp. 6139-6149, 2010.
155. L. Yang, J. Huang, X. Ren et al. , "Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis, " Cancer Cell, vol. 13, no. 1, pp. 23-35, 2008.
156. P. A. Aeed, M. Nakajima, and D. R. Welch, "The role of polymorphonuclear leukocytes (PMN) on the growth and metastatic potential of 13762NF mammary adenocarcinoma cells, " International Journal of Cancer, vol. 42, no. 5, pp. 748-759, 1988.
157. M. P. Colombo, L. Lombardi, A. Stoppacciaro et al. , "Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSFproducing and G-CSF-nonproducing tumor cells, " The Journal of Immunology, vol. 149, no. 1, pp. 113-119, 1992.
158. A. M. Hicks, G. Riedlinger, M. C. Willingham et al. , "Transferable anticancer innate immunity in spontaneous regression/ complete resistance mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 20, pp. 7753-7758, 2006.
159. J. Koch, J. Hau, J. Pravsgaard Christensen, H. Elvang Jensen, M. Bagge Hansen, and K. Rieneck, "Immune cells from SR/CR mice induce the regression of established tumors in BALB/c and C57BL/6 mice, " PLoS ONE, vol. 8, no. 3, Article IDe59995, 2013.
160. P. C. Kousis, B. W. Henderson, P. G. Maier, and S. O. Gollnick, "Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils, " Cancer Research, vol. 67, no. 21, pp. 10501-10510, 2007.
161. H. Suttmann, J. Riemensberger, G. Bentien et al. , "Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses, " Cancer Research, vol. 66, no. 16, pp. 8250-8257, 2006.
162. M. A. Lopez-Lago, S. Posner, V. J. Thodima, A. M. Molina, R. J. Motzer, and R. S. K. Chaganti, "Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression, " Oncogene, vol. 32, no. 14, pp. 1752-1760, 2013.
163. F. Dallegri, L. Ottonello, A. Ballestrero et al. , "Tumor cell lysis by activated human neutrophils: Analysis of neutrophildelivered oxidative attack and role of leukocyte functionassociated antigen 1, " Inflammation, vol. 15, no. 1, pp. 15-30, 1991.
164. M. Zivkovic, M. Poljak-Blazi, G. Egger, S. B. Sunjic, R. J. Schaur, and N. Zarkovic, "Oxidative burst and anticancer activities of rat neutrophils, " BioFactors, vol. 24, no. 1-4, pp. 305-312, 2005.
165. L. N. Bodduluru, E. R. Kasala, R. M. R. Madhana, and C. S. Sriram, "Natural killer cells: the journey frompuzzles in biology to treatment of cancer, " Cancer Letters, vol. 357, no. 2, pp. 454-467, 2015.
166. S. S. Metkar and C. J. Froelich, "Human neutrophils lack granzyme A, granzyme B, and perforin, " Blood, vol. 104, no. 3, pp. 905-906, 2004.
167. C. Wagner, C. Iking-Konert, B. Denefleh, S. Stegmaier, F. Hug, and G. M. Hansch, "Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils, " Blood, vol. 103, no. 3, pp. 1099-1104, 2004.
168. B. Stockmeyer, T. Beyer, W. Neuhuber et al. , "Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells, " Journal of Immunology, vol. 171, no. 10, pp. 5124-5129, 2003.
169. H. M. Rosevear, A. J. Lightfoot, M. A. O'Donnell, and T. S. Griffith, "The role of neutrophils and TNF-related apoptosisinducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder, " Cancer and Metastasis Reviews, vol. 28, no. 3-4, pp. 345-353, 2009.
170. E. L. Brincks, M. C. Risk, and T. S. Griffith, "PMN and antitumor immunity-the case of bladder cancer immunotherapy, " Seminars in Cancer Biology, vol. 23, no. 3, pp. 183-189, 2013.
171. A. T. Ludwig, J. M. Moore, Y. Luo et al. , "Tumor necrosis factorrelated apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity, " Cancer Research, vol. 64, no. 10, pp. 3386-3390, 2004.
172. S. Fulda, "Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL), " Advances in Experimental Medicine and Biology, vol. 818, pp. 167-180, 2014.
173. M. J. Martinez-Lorenzo, M. A. Alava, S. Gamen et al. , "Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells, " European Journal of Immunology, vol. 28, no. 9, pp. 2714-2725, 1998.
174. T. J. Kemp, A. T. Ludwig, J. K. Earel et al. , "Neutrophil stimulation with Mycobacteriumbovis bacillusCalmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L, " Blood, vol. 106, no. 10, pp. 3474-3482, 2005.
175. J.-L. Bodmer, P. Schneider, and J. Tschopp, "The molecular architecture of the TNF superfamily, " Trends in Biochemical Sciences, vol. 27, no. 1, pp. 19-26, 2002.
176. S. P. Cullen and S. J. Martin, "Fas and TRAIL death receptors as initiators of inflammation: implications for cancer, " Seminars in Cell and Developmental Biology, vol. 39, pp. 26-34, 2015.
177. J.-L. Bodmer, N. Holler, S. Reynard et al. , "TRAIL receptor-2 signals apoptosis through FADD and caspase-8, " Nature Cell Biology, vol. 2, no. 4, pp. 241-243, 2000.
178. G. P. Amarante-Mendes and T. S. Griffith, "Therapeutic applications of TRAIL receptor agonists in cancer and beyond, " Pharmacology and Therapeutics, vol. 155, pp. 117-131, 2015.
179. M. Balbin, A. Fueyo, A. M. Tester et al. , "Loss of collagenase-2 confers increased skin tumor susceptibility to male mice, " Nature Genetics, vol. 35, no. 3, pp. 252-257, 2003.
180. C. Rosales and E. Uribe-Querol, "Antibody-Fc receptor interactions in antimicrobial functions, " Current Immunology Reviews, vol. 9, no. 1, pp. 44-55, 2013.
181. W. Wang, A. K. Erbe, J. A. Hank, Z. S. Morris, and P. M. Sondel, "NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy, " Frontiers in Immunology, vol. 6, article 368, 2015.
182. M. van Egmond and J. E. Bakema, "Neutrophils as effector cells for antibody-based immunotherapy of cancer, " Seminars in Cancer Biology, vol. 23, no. 3, pp. 190-199, 2013.
183. C. Rosales and E. Uribe-Querol, "Fc receptors: cell activators of antibody functions, " Advances in Bioscience and Biotechnology, vol. 4, no. 4, pp. 21-33, 2013.
184. L. Ottonello, A. L. Epstein, M. Mancini, G. Tortolina, P. Dapino, and F. Dallegri, "Chimaeric Lym-1 monoclonal antibodymediated cytolysis by neutrophils fromG-CSF-treated patients: stimulation by GM-CSF and role of Fcγ-receptors, " British Journal of Cancer, vol. 85, no. 3, pp. 463-469, 2001.
185. T. Schneider-Merck, J. J. Lammerts van Bueren, S. Berger et al. , "Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage, " The Journal of Immunology, vol. 184, no. 1, pp. 512-520, 2010.
186. T. Valerius, R. Repp, T. P. M. de Wit et al. , "Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy, " Blood, vol. 82, no. 3, pp. 931-939, 1993.
187. Y. B. Su, A. J. Vickers, M. J. Zelefsky et al. , "Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer, " Cancer Journal, vol. 12, no. 3, pp. 182-188, 2006.
188. M. A. Otten, J. H. W. Leusen, E. Rudolph et al. , "FcR γ-chain dependent signaling in immature neutrophils is mediated by FcαRI, but not by FcγRI, " Journal of Immunology, vol. 179, no. 5, pp. 2918-2924, 2007.
189. J. E. Bakema, S. H. Ganzevles, D. M. Fluitsma et al. , "Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy, " Journal of Immunology, vol. 187, no. 2, pp. 726-732, 2011.
190. F. Dallegri, F. Patrone, G. Frumento, and C. Sacchetti, "Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms, " Journal of the National Cancer Institute, vol. 73, no. 2, pp. 331-339, 1984.
191. B. H. Kushner and N.-K. V. Cheung, "Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes, " Cancer Research, vol. 51, no. 18, pp. 4865-4870, 1991.
192. P. C. Rodriguez, D. G. Quiceno, J. Zabaleta et al. , "Arginase I production in the tumor microenvironment bymaturemyeloid cells inhibits T-cell receptor expression and antigen-specific Tcell responses, " Cancer Research, vol. 64, no. 16, pp. 5839-5849, 2004.
193. C. Beauvillain, Y. Delneste, M. Scotet et al. , "Neutrophils efficiently cross-prime naive T cells in vivo, " Blood, vol. 110, no. 8, pp. 2965-2973, 2007.
194. C. Tecchio, A. Micheletti, and M. A. Cassatella, "Neutrophilderived cytokines: facts beyond expression, " Frontiers in Immunology, vol. 5, article 508, 2014.
195. N. Branzk and V. Papayannopoulos, "Molecular mechanisms regulating NETosis in infection and disease, " Seminars in Immunopathology, vol. 35, no. 4, pp. 513-530, 2013.
196. V. Brinkmann, B. Laube, U. A. Abed, C. Goosmann, and A. Zychlinsky, "Neutrophil extracellular traps: how to generate and visualize them, " Journal of Visualized Experiments, vol. 36, article e1724, 2010.
197. V. Brinkmann and A. Zychlinsky, "Neutrophil extracellular traps: is immunity the second function of chromatin?" Journal of Cell Biology, vol. 198, no. 5, pp. 773-783, 2012.
198. P. R. Cooper, L. J. Palmer, and I. L. C. Chapple, "Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe?" Periodontology 2000, vol. 63, no. 1, pp. 165-197, 2013.
199. M. von Kockritz-Blickwede and V. Nizet, "Innate immunity turned inside-out: antimicrobial defense by phagocyte extracellular traps, " Journal ofMolecular Medicine, vol. 87, no. 8, pp. 775-783, 2009.
200. V. Papayannopoulos and A. Zychlinsky, "NETs: a new strategy for using old weapons, " Trends in Immunology, vol. 30, no. 11, pp. 513-521, 2009.
201. K. R. Short, M. von Kockritz-Blickwede, J. D. Langereis et al. , "Antibodiesmediate formation of neutrophil extracellular traps in the middle ear and facilitate secondary pneumococcal otitis media, " Infection and Immunity, vol. 82, no. 1, pp. 364-370, 2014.
202. E. Aleyd, M. W. M. van Hout, S. H. Ganzevles et al. , "IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I, " The Journal of Immunology, vol. 192, no. 5, pp. 2374-2383, 2014.
203. M. Behnen, C. Leschczyk, S. Moller et al. , "Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via Fcγ RIIIB and Mac-1, " Journal of Immunology, vol. 193, no. 4, pp. 1954-1965, 2014.
204. O. R. Aleman, N. Mora, R. Cortes-Vieyra, E. Uribe-Querol, and C. Rosales, "Differential use of human neutrophil Fcgamma receptors for inducing neutrophil extracellular trap (NET) formation, " Journal of Immunology Research, In press.
205. A. K. Gupta, P. Hasler, W. Holzgreve, S. Gebhardt, and S. Hahn, "Induction of neutrophil extracellularDNA lattices by placental microparticles and IL-8 and their presence in preeclampsia, " Human Immunology, vol. 66, no. 11, pp. 1146-1154, 2005.
206. S. Berger-Achituv, V. Brinkmann, U. A. Abed et al. , "A proposed role for neutrophil extracellular traps in cancer immunoediting, " Frontiers in Immunology, vol. 4, article 48, 2013.
207. M. Demers, D. S. Krause, D. Schatzberg et al. , "Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 32, pp. 13076-13081, 2012.
208. S. Sangaletti, C. Tripodo, C. Vitali et al. , "Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma, " Cancer Discovery, vol. 4, no. 1, pp. 110-129, 2014.
209. S. Huang, L. Mills, B. Mian et al. , "Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma, " The American Journal of Pathology, vol. 161, no. 1, pp. 125-134, 2002.
210. I. Walters, C. Austin, R. Austin et al. , "Evaluation of a series of bicyclic CXCR2 antagonists, " Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 2, pp. 798-803, 2008.
211. J. P. Quigley and E. I. Deryugina, "Combating angiogenesis early: potential of targeting tumor-recruited neutrophils in cancer therapy, " Future Oncology, vol. 8, no. 1, pp. 5-8, 2012.
212. C. Ginestier, S. Liu, M. E. Diebel et al. , "CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts, "The Journal of Clinical Investigation, vol. 120, no. 2, pp. 485-497, 2010.
213. E. Giraudo, M. Inoue, and D. Hanahan, "An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis, " Journal of Clinical Investigation, vol. 114, no. 5, pp. 623-633, 2004.
214. E. I. Deryugina, A. Zijlstra, J. J. Partridge et al. , "Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination, " Cancer Research, vol. 65, no. 23, pp. 10959-10969, 2005.
215. B. Fingleton, "MMPs as therapeutic targets-still a viable option?" Seminars in Cell and Developmental Biology, vol. 19, no. 1, pp. 61-68, 2008.
216. R. Clynes, "Antitumor antibodies in the treatment of cancer. Fc receptors link opsonic antibody with cellular immunity, " Hematology/Oncology Clinics of North America, vol. 20, no. 3, pp. 585-612, 2006.
217. T. Valerius, "Fcγ receptor polymorphisms as biomarkers for epidermal growth factor receptor antibodies, " Journal of Clinical Oncology, vol. 28, no. 23, article e393, 2010.
218. S. Derer, C. Kellner, S. Berger, T. Valerius, and M. Peipp, "Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function, " Methods in Molecular Biology, vol. 907, pp. 519-536, 2012.
219. S. Derer, P. Glorius, M. Schlaeth et al. , "Increasing FcaγRIIa affinity of an FcaγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity, " mAbs, vol. 6, no. 2, pp. 409-421, 2014.
220. J. E. Bakema and M. van Egmond, "Immunoglobulin A: a next generation of therapeutic antibodies?" mAbs, vol. 3, no. 4, pp. 352-361, 2011.
221. P. Boross, S. Lohse, M. Nederend et al. , "IgA EGFR antibodies mediate tumour killing in vivo, " EMBOMolecularMedicine, vol. 5, no. 8, pp. 1213-1226, 2013.
222. A. M. Brandsma, T. Ten Broeke, M. Nederend et al. , "Simultaneous targeting of FcγRs and FcαRI enhances tumor cell killing, " Cancer Immunology Research, vol. 3, no. 12, pp. 1316-1324, 2015.